Research Highlights: Transgender and gender-diverse people have higher rates of hypertension compared to the general population. Within two to four months of starting gender-affirming hormone therapy, transgender women had a lower average systolic blood pressure, and transgender men had a higher average systolic blood pressure. Clinicians should consistently monitor blood pressure before and after starting gender-affirming hormone therapy to take hypertension prevention measures. Embargoed until 4 a.m. CT/5 a.m. ET Monday, April 19, 2021 (NewMediaWire) - April 19, 2021 - DALLAS - Gender-affirming hormone therapy (GAHT) was associated with blood pressure changes in both transgender men and women, according to new research published today in Hypertension, an American Heart Association journal. Given the higher burden of heart attack, stroke and other cardiovascular conditions among transgender men and women, blood pressure screening and monitoring are important, especially after beginning hormone therapies. Although doctors have prescribed gender-affirming hormone therapy to transgender men and women for more than 25 years, researchers and health care professionals know little about rates of hypertension and how the effects on blood pressure change over time. Previous research has shown that transgender men were almost five times as likely to report having a heart attack compared to cisgender women. Conversely, transgender women were more than two-and-a-half times more likely to have reported a heart attack than cisgender women, yet they did not have a significant increase in heart attack incidence when compared with cisgender men. However, a systematic review conducted in 2020 found most of the studies examining gender-affirming hormones and blood pressure had sample sizes that were too small to detect statistically significant differences in blood pressure. “There are many important gaps in our knowledge about the effects of hormone therapy for transgender people. This study examined the time course and magnitude of the effects of gender-affirming hormones on blood pressure,” said senior study author Michael S. Irwig, M.D., an associate professor of medicine at Harvard Medical School and director of transgender medicine at Beth Israel Deaconess Medical Center in Boston. To conduct the largest and longest observational study of its kind, the researchers followed 470 patients who began GAHT at a medical center in the Washington, D.C. area from 1/1/2007 to 6/1/2015. Participants were all at least 17 years old and non-cisgender. Of the 470 patients, 247 were transfeminine and 223 were transmasculine. About 27% of the participants were non-white, and 16% self-identified as Latinx. Researchers measured each patient’s blood pressure before beginning GAHT to establish a baseline and continued measurements at subsequent clinical visits for up to 57 months. The study found: Within two to four months of beginning hormone therapy, transgender women saw an average decrease of 4.0 mm Hg in their systolic blood pressure, but transgender men saw an average increase of 2.6 mm Hg. The prevalence of stage 2 hypertension (at least 140/90 mm Hg) dropped from 19% to 10% in the transfeminine group within two to four months of beginning hormone therapy. The use of testosterone in transgender men could lead to an increased risk for heart attack or stroke if they also have untreated high blood pressure. In addition, the results indicated that some patients experienced different blood pressure effects compared to the majority of those with the same gender identity. Some transgender women and transgender men saw blood pressure rates trend in the opposite direction of their peers. The study authors highlight this is an area that requires further research, noting individuals taking the same medication may react in different ways. The study has several limitations. Most patients were on the same formulation of intramuscular ...

Highlights: To date, no adverse cardiac events related to SARS-CoV-2 infection have been observed among more than 3,000 collegiate athletes during short-term clinical surveillance. Findings suggest safe return-to-play without cardiac testing for asymptomatic or mildly symptomatic athletes. Embargoed until 12:00 p.m. CDT / 1:00 p.m. EDT April 17, 2021 (NewMediaWire) - April 17, 2021 - DALLAS - While the lasting impact of COVID-19 on hospitalized patients in the general population is common and associated with adverse cardiac outcomes, evaluations of cardiac involvement of more than 3,000 college-aged, competitive athletes revealed no adverse cardiac events following COVID-19 infections and indicate a safe return-to-play for asymptomatic and mildly symptomatic athletes without additional cardiac testing, according to a study published today in the American Heart Association’s flagship journal Circulation. In this prospective, multicenter, observational cohort study with data collected from September 1 to December 31, 2020, from 42 colleges and universities in the U.S., researchers assessed the prevalence, clinical characteristics and outcomes of SARS-CoV-2 cardiac involvement among collegiate athletes using the Outcomes Registry for Cardiac Conditions in Athletes (ORCCA). ORCCA is a national registry, or research database, to track COVID-19 cases and heart-related impacts in NCAA athletes to drive improvements in screening and inform our understanding of cardiac involvement in college athletes who have had COVID-19. “The very timely and largely reassuring data coming from the ORCCA registry were made possible by an amazing collaborative effort between the sports medicine and sports cardiology communities,” said Aaron L. Baggish, M.D., co-principal investigator and director of the Cardiovascular Performance Program at Massachusetts General Hospital in Boston. “It is anticipated that ORCCA will continue to shape the way we protect the health of young competitive athletes well beyond the end of the COVID-19 pandemic.” Out of more than 19,000 athletes tested for SARS-CoV-2 infection, 3,018 tested positive for COVID-19 and underwent cardiac evaluation. A total of 2,820 athletes underwent at least one element of cardiac ‘triad’ testing (12-lead electrocardiography (ECG), troponin, and/or transthoracic echocardiography(TTE)), followed by cardiac magnetic resonance (CMR) if clinically indicated; and 198 athletes underwent a primary screening CMR. Overall, the prevalence of probable or definite cardiac involvement from SARS-CoV-2 infection was 0.4%-1.5%. The diagnostic yield for probable or definite cardiac involvement was 6.7 times higher for a CMR obtained for clinical reasons (10.1%) versus a primary screening CMR (1.5%). The odds of having cardiac involvement was also 3.1 times higher in athletes with cardiopulmonary symptoms. “This was an amazing collaboration within the sports medicine and cardiology community,” said Jonathan A. Drezner, M.D., director of the UW Medicine Center for Sports Cardiology in Seattle and a co-principal investigator of the study. “Most athletes with no symptoms or mild illness from SARS-CoV-2 can return to sports safely without additional cardiac testing as long as they feel good on return to exercise and don’t have cardiopulmonary symptoms like chest pain.” The American Heart Association and the American Medical Society for Sports Medicine (AMSSM) joined forces earlier this year to accelerate a critical new research initiative studying cardiac conditions in athletes, in part to speed new insights into the impact of COVID-19 to the cardiovascular system of college athletes and safety of return to play after diagnosis. The collaborative data registry will aid research on COVID-19, and, long-term, develop a deep knowledge base on cardiac disease in athletes beyond the pandemic. The registry has been developed with participation from the NCAA and has more than 60 schools currently contributing to the registry. Schools interested in participating or learning more about the registry can send an ...

Tulsa, OK - (NewMediaWire) - April 16, 2021 - AppSwarm, Corp. (OTC: SWRM), a software development company and aggregator of mobile applications, announced the launch of http://dogelabs.io/ to develop commercial applications around the Dogecoin blockchain protocol.The Company announces the launch of DogeLabs.io, which will embark on application research, seminars, blockchain workshops, and will utilize its video conferencing capabilities to bring together global minds and developer insights around the Doge community. http://dogelabs.io/Application DevelopmentDogeLabs will work on leveraging Doge’s underlying liquidity to develop commercial applications that utilize Dogecoin blockchain for mobile and web-based products.Why Dogecoin?Doge offers high liquidity, fast transaction speed, and brand popularity, which could make it a unique protocol on which to build new commercial applications such as money transfers, micropayments, in-app purchases, and customer rewards.Developers recently released a new version of the protocol's core that promises improved synchronization speed and reduced default mempool expiry time.Developers say they've significantly improved the speed at which a DOGE node can upload blocks, by removing expensive integrity checks that were performed each time a block is sent to another node. Startup AcceleratorDogeLabs, in conjunction with TulsaLabs.io, is launching a startup accelerator that will assist in providing access to seed funding, training and mentorship to blockchain startups to help them pass successfully through the early stages of business growth.Our labs goal is to provide investments for novel ideas developers may have seeking to build commercial applications or integrate current blockchain protocols around their existing business models.Partnerships and CollaborationsTulsaLabs.io is currently seeking companies and blockchain developers who wish to explore integrating Doge protocol into new and exciting mobile and web-based application products. http://dogelabs.io/partner-with-us/The company will be announcing new members to its blockchain advisory board in the coming weeks as we embark on building a premier blockchain development consulting and research firm headquartered in Tulsa, OK.About APPSWARMAppSwarm is a technology company specializing in accelerated development and publishing of mobile apps and other software platforms for gaming and business applications and seeks to acquire symmetric business opportunities. AppSwarm partners with and assists other development firms in technology development, business management, and funding needs.For more information, follow us on www.app-swarm.com FaceBook www.facebook.com/AppSwarm Twitter https://twitter.com/AppSwarm or Instagram https://www.instagram.com/appswarm/“LEGAL”DogeLabs is strictly a research firm focused on the development of blockchain applications, and in no way is involved with the buying, selling, issuance of any cryptocurrencies, or investment advice.Forward-Looking Statements:"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release may contain forward-looking statements that are subject to risk and uncertainties including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk, and other risks detailed from time to time in the Company's filings with OTCMarkets.com and as required to the Securities and Exchange Commission. These risks could cause SWRM's actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, the Company.Investor and Media Contacts:AppSwarm, Corp.888-886-8583info@app-swarm.com

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - April 16, 2021 - Neovasc Inc.("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021. The Company is collaborating with its European Notified Body (the “Notified Body”) on potential next steps. Neovasc has been working with its Notified Body for more than a year to obtain a decision on a CE Mark for Tiara TA, including an ongoing exchange of additional information beyond the original submission. The Company has determined that it will be unable to provide the additional information required by the Notified Body, which includes further testing data, before the current MDD regulations end next month. The MDD is set to be replaced by the newer Medical Device Regulation (“MDR”) on May 26, 2021. A CE Mark under either the MDD or MDR regulations would allow the Company to commercialize the Tiara TA system in Europe.“We are disappointed that the MDD regulations are going to be replaced before we are able to gain CE Mark approval for the Tiara TA system,” said Fred Colen, Chief Executive Officer Neovasc. “We believe that the Tiara valve has shown to be a remarkable device and we are pleased with the safety and efficacy profile the device has displayed in clinical trials to date. Our team has worked tirelessly, and we believe we have made meaningful progress with our notified body during COVID-19 lockdowns to advance the approval process, but we have run out of time to complete the review before the transition to MDR next month, our previously announced target date for a CE mark decision.”The Company expects to provide an update at, or around, the upcoming Q1 2021 Earnings Call scheduled for early May.The transition from MDD to MDR does not impact the Tiara transfemoral program (“Tiara TF”). The Company has always anticipated that Tiara TF’s CE Mark submission would be assessed under MDR.About Neovasc Inc. Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. The Company is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. Its products include Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe. For more information, visit: www.neovasc.com. Investors Mike Cavanaugh Westwicke/ICR Phone: +1.646.877.9641 Mike.Cavanaugh@westwicke.com Media Sean Leous Westwicke/ICR Phone: +1.646.866.4012 Sean.Leous@westwicke.com Forward-Looking Statement Disclaimer Certain statements in this news release contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws that may not be based on historical fact. When used herein, the words "expect", "anticipate", "estimate", "may", "will", "should", "intend," "believe", and similar expressions, are intended to identify forward-looking statements. Forward-looking statements may involve, but are not limited to expectations as to the growing cardiovascular marketplace, the safety and efficacy profile of the Tiara TA, the Company’s plans to evaluate all feedback from the notified body and strategic alternatives, and the anticipated submission and assessment of the Tiara TF under the MDR rules at the time of submission. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the doubt about the Company’s ...

Dallas, TX - (NewMediaWire) - April 16, 2021 - NaturalShrimp, Inc. (OTCQB: SHMP), the aquaculture Company that has developed and patented the first commercially-operational RAS (Recirculating Aquaculture System), has begun transferring shrimp from nursery to grow-out tanks in its La Coste, Texas production facility. The production facility contains twenty 2,000-gallon nursery tanks and forty 20,000-gallon tanks. This combination minimizes the amount of square footage required for production. In addition, the smaller nursery tanks provide a more controlled environment for acclimating the initial postlarvae (PL) shrimp to the facility’s water temperature and salinity while still providing enough volume for the smaller shrimp to grow. The Company has successfully begun gravity flowing shrimp who have reached their transfer size from nursery tanks where they were previously stocked into the larger grow-out tanks where they will remain until they reach harvest size.Photos of the transfer can be found on the NaturalShrimp website at https://naturalshrimp.com/under this press release headline.ABOUT NATURALSHRIMP: NaturalShrimp, Inc. is a publicly traded aquaculture Company, headquartered in Dallas, with production facilities located near San Antonio, Texas and Webster City, Iowa. The Company has developed the first commercially viable system for growing shrimp in enclosed, salt-water systems, using patented technology to produce fresh, never frozen, naturally grown shrimp, without the use of antibiotics or toxic chemicals. NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp.Forward-Looking StatementsThis press release contains "forward-looking statements." The statements contained in this press release that are not purely historical are forward-looking statements. Forward-looking statements give the Company's current expectations or forecasts of future events. Such statements are subject to risks and uncertainties that are often difficult to predict and beyond the Company's control and could cause the Company's results to differ materially from those described. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements include statements regarding moving forward with executing the Company's global growth strategy.The statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict. The Company is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as required by law. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends affecting the financial condition of our business.Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Important factors that could cause such differences include but are not limited to the Risk Factors and other information set forth in the Company's Annual Report on Form 10-K filed on March 30, 2015, and in our other filings with the U.S. Securities and Exchange Commission.Contact: Paul Knopick940.262.3584pknopick@eandecommunications.com

Suwanee, GA - (NewMediaWire) - April 16, 2021 - SANUWAVE Health, Inc. (OTCQB: SNWV), a leading provider of next-generation wound care products, announced today that the Company will be participating in a number of leading wound care industry conferences – both virtual and in-person – where it will highlight the clinical merits of its “Energy First” protocols and showcase how its end-to-end portfolio of non-invasive and biologic-response therapeutic solutions address the entire wound care continuum.SANUWAVE is currently scheduled to participate in the following industry events:SuperBones SuperWounds East 2021VirtualApril 17-18Advanced Wound Care Conference (AWCC)New Orleans, LAMay 7SAWC Spring Virtual Wound Care WeekVirtualMay 10-14LSI 2021 Emerging MedTech SummitDana Point, CAMay 11-13Wound Care Business Meetings 2021Philadelphia, PAJune 11Midwest Podiatry ConferenceVirtualJune 17-20Wound Care Business Meetings 2021Atlanta, GAJune 25“We are excited to share SANUWAVE’s new brands with the country’s leading wound care specialists at upcoming industry conferences, starting with the SuperBones event on April 18th, where we will discuss the coding, billing and reimbursement for our ‘Energy First’ products,” stated Kevin A. Richardson, II, Chairman and Chief Executive Officer of SANUWAVE Health. “SANUWAVE will continue to educate the industry on the clinical merits of our ‘Energy First’ products and how they improve clinical outcomes for those patients with chronic, non-healing wounds. We invite everyone to visit us at our booths at these conferences—whether virtual or in-person—and learn what the new SANUWAVE suite of solutions has to offer.” About SANUWAVE SANUWAVE Health, Inc. (OTCQB: SNWV) is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medical products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac/endovascular conditions. For more information, please visit. www.SANUWAVE.com.Forward-Looking StatementsThis press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief, or current expectations of the company, its directors, or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions, and factors that may affect operating results, performance, and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.Media CONTACT: Jane ByramSCORR Marketing512.626.2758jane@scorrmarketing.com